Pharma RSS Digest - 2026-07-21

Overview

Today's digest is dominated by deal-making across the pharma value chain. Two of the three lead stories involve corporate transactions — Cardinal Health's tuck-in home-care acquisitions and Samsung Biologics's planned acquisition of Swiss peptide CDMO PolyPeptide — while a third anchors the week in early-stage biotech financing via Rege Nephro's bridge raise. The thread connecting the M&A items is consolidation around high-demand therapeutic and service adjacencies: chronic-disease home delivery and GLP-1-era peptide manufacturing. With no failed stories in the window, the tape is light on negative catalysts but rich on strategic intent. Watchlist items add texture around pharmacovigilance, regenerative-medicine regulatory strategy, and a forward-looking ESMO data preview.

Key Developments

Samsung Biologics launched an all-cash tender offer for PolyPeptide at CHF 44.31 per share, implying roughly CHF 1.46 billion in equity value and a 40% premium to PolyPeptide's undisturbed April 2026 price. PolyPeptide's board, acting through independent members, unanimously recommended acceptance, and its largest shareholder (~55.65%) has signaled support. The deal matters because it would extend Samsung Biologics from antibodies and ADCs into peptide CDMO — squarely in the GLP-1 and oncology demand corridor — and add manufacturing sites across Sweden, Belgium, France, the U.S., and India. Watch next for tender-acceptance progress above the 66⅔% threshold, multi-jurisdiction antitrust review, and the closing timeline (guided to year-end 2026).

Cardinal Health partnership update

Cardinal Health agreed to acquire AdaptHealth's Diabetes Health business and Strive Medical for approximately $360 million in cash, folding both into its at-Home Solutions unit. The two targets together serve more than 245,000 patients annually in diabetes and urology/wound/ostomy/incontinence care, layering onto the platform Cardinal built around its earlier Advanced Diabetes Supply deal. Management framed the transactions as accretive to non-GAAP earnings within 12 months of close and pointed to integration milestones — 500,000 onboarded customers and the ContinuCare Pathway digital referral program — as evidence of execution capacity. Watch next for closing on regulatory approvals, allocation of the $360 million between the two targets, and any channel-conflict commentary when Cardinal reports integration costs.

Samsung Biologics partnership update

Rege Nephro closed approximately $10.6 million via J-KISS share acquisition rights to advance its kidney-disease pipeline. Lead asset RN-014, a small-molecule therapy for autosomal dominant polycystic kidney disease (ADPKD), recently completed Last Patient Last Visit in a Phase 2a trial, with data analysis now underway. Proceeds are earmarked for RN-014 commercialization and global licensing/partnering, nonclinical work on iPS-cell-derived RN-032, broader discovery, and team buildout. The raise matters because it reflects continued Japanese investor appetite for rare-kidney and regenerative-medicine bets, and positions the company for an anticipated Series C. Watch next for Phase 2a topline data, any out-licensing announcement for RN-014, and Series C timing.

Rege Nephro funding update

Watchlist

• Cetirizine recall: Unique Pharmaceutical Laboratories (a division of J. B. Chemicals & Pharmaceuticals) is voluntarily recalling four lots of cetirizine hydrochloride 5 mg tablets over potential ranitidine cross-contamination; distributed nationwide via Rising Pharma Holdings. No adverse events reported to date. Watch for root-cause disclosure and any FDA follow-up on shared-line controls. [link]
• Neuronata-R (lenzumestrocel) retains South Korean conditional approval: South Korea's MFDS updated the label with Phase 3 ALSUMMIT data, which missed in the full population but met endpoints in slow progressors, including NfL biomarker reduction. CorestemChemon plans full-scale manufacturing resumption, international patient access, and an FDA BLA filing targeted for 2027. Watch for Type C meeting outcomes and any NfL regulatory positioning from FDA or EMA. [link]
• Franchise Equity Partners acquires Bravo Fit: FEP is buying Planet Fitness's Australian franchisee (32 clubs, development rights toward ~100 additional units across five regions), with Planet Fitness exiting its minority stake. Terms undisclosed. Watch for announced expansion cadence and any further FEP Australian deals. [link]
• Mabwell to present Nectin-4 ADC data at ESMO 2026: 9MW2821 (Bulumtatug Fuvedotin) Phase 2 results in triple-negative breast cancer patients previously treated with topoisomerase I inhibitor–based ADCs will be featured in an oral presentation on October 26 in Madrid. Watch for the topline efficacy and safety readout, which could reshape competitive positioning in the Nectin-4 ADC space. [link]